Office ofthe Director
Bureau ofCompetition

UNITED STATES OF AMERICA

FEDERAL TRADE COMMISSION WASHINGTON, D.C 20580

MAR 102009

Michael F. Brockmeyer, Esq.
Frommer Lawrence & Haug LLP
1667 K Street, NW
Washington, DC 20006

Re: UCB Pharma Inc./Keppra, FTC File No. 081-0031

Dear Mr. Brockmeyer:

The Federal Trade Commission's Bureau ofCompetition conducted a nonpublic
investigation to determine whether your client, My1an Laboratories, Inc., had engaged or was engaging in, unfair methods of competition in or affecting commerce in violation of Section 5 of the Federal Trade Commission Act, 15 U.S.C. § 45, as amended, with respect to the sale of Keppra or its generic equivalents.

Upon reviewing this matter, it now